PMI 002Alternative Names: PMI-002
Latest Information Update: 21 Aug 2009
At a glance
- Originator Phytomedics
- Class Antineoplastics; Phytotherapies
- Mechanism of Action Apoptosis stimulants; JNK mitogen-activated protein kinase inhibitors; Multidrug resistance-associated protein 1 inhibitors; P-glycoprotein inhibitors; Phosphotransferase modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 21 Aug 2009 Preclinical development is ongoing in USA
- 24 Oct 2003 Preclinical trials in Cancer in USA (unspecified route)